You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

Cefixime - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cefixime and what is the scope of freedom to operate?

Cefixime is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Lupin Ltd, Aurobindo Pharma Ltd, Belcher, Chartwell Rx, Lederle, and Lupin Pharms, and is included in fourteen NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Cefixime has two patent family members in two countries.

There are fourteen drug master file entries for cefixime. Eight suppliers are listed for this compound.

Summary for cefixime
International Patents:2
US Patents:1
Tradenames:2
Applicants:7
NDAs:14
Drug Master File Entries: 14
Finished Product Suppliers / Packagers: 8
Raw Ingredient (Bulk) Api Vendors: 72
Clinical Trials: 35
Patent Applications: 7,364
Drug Prices: Drug price trends for cefixime
What excipients (inactive ingredients) are in cefixime?cefixime excipients list
DailyMed Link:cefixime at DailyMed
Drug Prices for cefixime

See drug prices for cefixime

Recent Clinical Trials for cefixime

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 2
Haiphong University of Medicine and PharmacyPhase 2
Universidad Peruana Cayetano HerediaPhase 3

See all cefixime clinical trials

Pharmacology for cefixime
Medical Subject Heading (MeSH) Categories for cefixime
Paragraph IV (Patent) Challenges for CEFIXIME
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SUPRAX for Oral Suspension cefixime 500 mg/5 mL 202091 1 2016-07-22

US Patents and Regulatory Information for cefixime

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd SUPRAX cefixime FOR SUSPENSION;ORAL 202091-001 Feb 20, 2013 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lupin Pharms SUPRAX cefixime FOR SUSPENSION;ORAL 065129-001 Feb 23, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Belcher CEFIXIME cefixime FOR SUSPENSION;ORAL 206938-001 Feb 6, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-002 Oct 25, 2010 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alkem Labs Ltd CEFIXIME cefixime CAPSULE;ORAL 210574-001 Oct 9, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Pharms SUPRAX cefixime TABLET;ORAL 065130-001 Feb 12, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Pharms SUPRAX cefixime FOR SUSPENSION;ORAL 065355-001 Apr 10, 2007 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.